Published in J Clin Invest on January 01, 2008
Apc Restoration Promotes Cellular Differentiation and Reestablishes Crypt Homeostasis in Colorectal Cancer. Cell (2015) 3.54
Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers. Nature (2014) 2.75
mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. Cell Stem Cell (2009) 2.74
A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J Cell Biol (2011) 2.19
Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras. Proc Natl Acad Sci U S A (2008) 2.14
New insights of epithelial-mesenchymal transition in cancer metastasis. Acta Biochim Biophys Sin (Shanghai) (2008) 1.94
Regulation of transgenes in three-dimensional cultures of primary mouse mammary cells demonstrates oncogene dependence and identifies cells that survive deinduction. Genes Dev (2009) 1.76
Snail: More than EMT. Cell Adh Migr (2010) 1.53
How genetically engineered mouse tumor models provide insights into human cancers. J Clin Oncol (2011) 1.43
Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis. Neuro Oncol (2013) 1.32
Metastatic pancreatic cancer is dependent on oncogenic Kras in mice. PLoS One (2012) 1.27
Epithelial-mesenchymal transition and tumor suppression are controlled by a reciprocal feedback loop between ZEB1 and Grainyhead-like-2. Cancer Res (2013) 1.27
The pathology of EMT in mouse mammary tumorigenesis. J Mammary Gland Biol Neoplasia (2010) 1.21
Wnt-β-catenin signaling protects against hepatic ischemia and reperfusion injury in mice. Gastroenterology (2011) 1.19
Metastasis suppressor genes at the interface between the environment and tumor cell growth. Int Rev Cell Mol Biol (2011) 1.18
Pathways to breast cancer recurrence. ISRN Oncol (2013) 1.15
Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction. Proc Natl Acad Sci U S A (2011) 1.13
Defining the ATM-mediated barrier to tumorigenesis in somatic mammary cells following ErbB2 activation. Proc Natl Acad Sci U S A (2010) 1.09
Cervical cancers require the continuous expression of the human papillomavirus type 16 E7 oncoprotein even in the presence of the viral E6 oncoprotein. Cancer Res (2012) 0.92
Ink4a/Arf(-/-) and HRAS(G12V) transform mouse mammary cells into triple-negative breast cancer containing tumorigenic CD49f(-) quiescent cells. Oncogene (2013) 0.81
ARF inhibits the growth and malignant progression of non-small-cell lung carcinoma. Oncogene (2013) 0.79
p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia. Oncotarget (2015) 0.79
The quiescent cellular state is Arf/p53-dependent and associated with H2AX downregulation and genome stability. Int J Mol Sci (2012) 0.78
Notch3 inhibits epithelial-mesenchymal transition by activating Kibra-mediated Hippo/YAP signaling in breast cancer epithelial cells. Oncogenesis (2016) 0.78
Primary cilia modulate balance of canonical and non-canonical Wnt signaling responses in the injured kidney. Fibrogenesis Tissue Repair (2015) 0.77
Surfing the p53 network. Nature (2000) 35.36
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42
The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol (2000) 21.15
Wnt signaling and cancer. Genes Dev (2000) 18.53
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med (2006) 17.08
Tumor spectrum analysis in p53-mutant mice. Curr Biol (1994) 16.60
The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol (2000) 15.78
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A (2005) 13.54
Convergence of Wnt, beta-catenin, and cadherin pathways. Science (2004) 13.13
Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell (1997) 12.41
Role of the INK4a locus in tumor suppression and cell mortality. Cell (1996) 11.41
Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol (2002) 10.95
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89
Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol Cell Biol (2002) 8.60
Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev (2003) 8.00
Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature (2001) 7.06
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev (1999) 6.87
A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell (2002) 6.76
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature (2007) 6.56
Dissecting p53 tumor suppressor functions in vivo. Cancer Cell (2002) 6.24
Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A (2006) 5.90
The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell (2005) 5.81
Snail blocks the cell cycle and confers resistance to cell death. Genes Dev (2004) 5.34
Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov (2006) 5.29
The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov (2006) 5.11
Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A (1998) 4.99
INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev (1999) 4.13
Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A (2007) 3.37
An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell (2004) 3.30
Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2006) 3.04
Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/beta -catenin signaling is activated in human colon tumors. Proc Natl Acad Sci U S A (2001) 2.77
HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res (2006) 2.74
Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev (2003) 2.27
Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. Am J Pathol (2002) 2.26
The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nat Genet (1995) 2.02
Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci U S A (2006) 1.89
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc Natl Acad Sci U S A (2006) 1.71
Histologically normal human mammary epithelia with silenced p16(INK4a) overexpress COX-2, promoting a premalignant program. Cancer Cell (2004) 1.66
Down-regulation of beta-catenin by activated p53. Mol Cell Biol (2001) 1.60
Lapatinib: current status and future directions in breast cancer. Oncologist (2006) 1.43
Sox10 is required for the early development of the prospective neural crest in Xenopus embryos. Dev Biol (2003) 1.32
Deletion and altered regulation of p16INK4a and p15INK4b in undifferentiated mouse skin tumors. Cancer Res (1995) 1.32
Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo. Oncogene (2003) 1.29
Endocrine therapy--current benefits and limitations. Breast Cancer Res Treat (2005) 1.21
Selective inactivation of p53 facilitates mouse epithelial tumor progression without chromosomal instability. Mol Cell Biol (2001) 1.16
p19(ARF) is dispensable for oncogenic stress-induced p53-mediated apoptosis and tumor suppression in vivo. Mol Cell Biol (2002) 1.12
Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms. J Pathol (2003) 1.05
Steroid receptors and their role in the biology and control of breast cancer growth. Semin Oncol (2006) 1.05
Regulation of the Arf tumor suppressor in Emicro-Myc transgenic mice: longitudinal study of Myc-induced lymphomagenesis. Blood (2006) 1.05
Prevalence of aberrant methylation of p14ARF over p16INK4a in some human primary tumors. Mutat Res (2003) 1.04
Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment. Endocr Relat Cancer (2005) 0.97
Advances in adjuvant therapy for breast cancer. Clin Adv Hematol Oncol (2006) 0.94
The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis. Cancer Res (2003) 0.91
A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer. Cancer Treat Rev (2005) 0.86
Flipping the oncogene switch: illumination of tumor maintenance and regression. Trends Genet (2000) 0.84
Spectral karyotyping of sarcomas and fibroblasts derived from Ink4a/Arf-deficient mice reveals chromosomal instability in vitro. Int J Oncol (2005) 0.80
Targeting oncogene dependence and resistance. Cancer Cell (2003) 0.79
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol (2003) 8.12
The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell (2005) 5.81
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature (2004) 5.61
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 5.31
PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell (2003) 5.13
Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood (2002) 4.88
Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol (2007) 4.67
Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell (2002) 4.36
Global regulation of erythroid gene expression by transcription factor GATA-1. Blood (2004) 4.22
Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell (2006) 4.15
The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev (2003) 3.79
Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell (2005) 3.68
Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci U S A (2003) 3.61
Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J Proteome Res (2007) 3.48
Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res (2004) 3.43
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov (2013) 3.25
A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology. FASEB J (2002) 3.05
A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat Biotechnol (2011) 2.91
Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity. Nat Cell Biol (2013) 2.90
CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest (2011) 2.90
Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci U S A (2002) 2.89
Hlx is induced by and genetically interacts with T-bet to promote heritable T(H)1 gene induction. Nat Immunol (2002) 2.87
Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Cancer Res (2004) 2.84
mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. Cell Stem Cell (2009) 2.74
Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression. Proc Natl Acad Sci U S A (2007) 2.64
Differential regulation of the transcriptional activities of hypoxia-inducible factor 1 alpha (HIF-1alpha) and HIF-2alpha in stem cells. Mol Cell Biol (2006) 2.56
Syngeneic mouse mammary carcinoma cell lines: two closely related cell lines with divergent metastatic behavior. Clin Exp Metastasis (2005) 2.52
GATA-1-mediated proliferation arrest during erythroid maturation. Mol Cell Biol (2003) 2.52
Prostatic intraepithelial neoplasia in genetically engineered mice. Am J Pathol (2002) 2.48
Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer (2007) 2.41
Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res (2002) 2.29
Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev (2003) 2.27
Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. Am J Pathol (2002) 2.26
Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol (2007) 2.23
Computational expression deconvolution in a complex mammalian organ. BMC Bioinformatics (2006) 2.18
The Ets transcription factor Elf5 specifies mammary alveolar cell fate. Genes Dev (2008) 2.13
Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res (2003) 2.11
Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell (2004) 2.08
Developmental context determines latency of MYC-induced tumorigenesis. PLoS Biol (2004) 2.05
Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A (2009) 2.01
Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell (2010) 1.88
HIF-2alpha deletion promotes Kras-driven lung tumor development. Proc Natl Acad Sci U S A (2010) 1.86
Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice. Proc Natl Acad Sci U S A (2008) 1.84
Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Res (2004) 1.84
ShcA signalling is essential for tumour progression in mouse models of human breast cancer. EMBO J (2008) 1.82
Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol (2008) 1.74
Analysis of cell migration using whole-genome expression profiling of migratory cells in the Drosophila ovary. Dev Cell (2006) 1.73
Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. J Clin Invest (2009) 1.67
Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. Cancer Res (2004) 1.67
Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res (2013) 1.66
Enhanced in vivo bioluminescence imaging using liposomal luciferin delivery system. J Control Release (2009) 1.60
Maternal dioxin exposure combined with a diet high in fat increases mammary cancer incidence in mice. Environ Health Perspect (2010) 1.60
Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer. Cancer Res (2008) 1.59
Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy. J Clin Invest (2015) 1.58
PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev (2004) 1.58
Persistent parity-induced changes in growth factors, TGF-beta3, and differentiation in the rodent mammary gland. Mol Endocrinol (2002) 1.56
STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas. Breast Cancer Res (2012) 1.56
T-cadherin supports angiogenesis and adiponectin association with the vasculature in a mouse mammary tumor model. Cancer Res (2008) 1.54
Effects of FVB/NJ and C57Bl/6J strain backgrounds on mammary tumor phenotype in inducible nitric oxide synthase deficient mice. Transgenic Res (2007) 1.54
SLITs suppress tumor growth in vivo by silencing Sdf1/Cxcr4 within breast epithelium. Cancer Res (2008) 1.52
Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors. Cancer Res (2011) 1.52
Bcl-X(L) affects Ca(2+) homeostasis by altering expression of inositol 1,4,5-trisphosphate receptors. Proc Natl Acad Sci U S A (2002) 1.51
E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemia. Blood (2003) 1.51
Kinase-inactive glycogen synthase kinase 3beta promotes Wnt signaling and mammary tumorigenesis. Cancer Res (2005) 1.50
PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine. J Nucl Med (2011) 1.50
c-Myc transforms human mammary epithelial cells through repression of the Wnt inhibitors DKK1 and SFRP1. Mol Cell Biol (2007) 1.50
EMT tumorigenesis in the mouse mammary gland. Lab Invest (2007) 1.47
A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci U S A (2004) 1.47
Deregulated estrogen receptor alpha expression in mammary epithelial cells of transgenic mice results in the development of ductal carcinoma in situ. Cancer Res (2005) 1.46
Activation of beta -catenin signaling in differentiated mammary secretory cells induces transdifferentiation into epidermis and squamous metaplasias. Proc Natl Acad Sci U S A (2002) 1.44
Ets2-dependent stromal regulation of mouse mammary tumors. Mol Cell Biol (2003) 1.43
ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res (2010) 1.43
Activation of different Wnt/beta-catenin signaling components in mammary epithelium induces transdifferentiation and the formation of pilar tumors. Oncogene (2002) 1.43
Krüppel-like factor 4 inhibits tumorigenic progression and metastasis in a mouse model of breast cancer. Neoplasia (2011) 1.39
Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ. Clin Cancer Res (2006) 1.39
Functional microarray analysis of mammary organogenesis reveals a developmental role in adaptive thermogenesis. Mol Endocrinol (2002) 1.39
A lysosomal tetraspanin associated with retinal degeneration identified via a genome-wide screen. EMBO J (2004) 1.39
Activation of beta-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation. Oncogene (2003) 1.37
In vivo positron-emission tomography imaging of progression and transformation in a mouse model of mammary neoplasia. Proc Natl Acad Sci U S A (2004) 1.37
Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors. Mol Cell Biol (2003) 1.36
Isoform-specific requirement for Akt1 in the developmental regulation of cellular metabolism during lactation. Cell Metab (2006) 1.36
Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary tumorigenesis. Mol Cell Biol (2006) 1.34
Oncogenic signaling pathways activated in DMBA-induced mouse mammary tumors. Toxicol Pathol (2005) 1.34
Polyomavirus middle T-induced mammary intraepithelial neoplasia outgrowths: single origin, divergent evolution, and multiple outcomes. Mol Cancer Ther (2004) 1.33
From whence will they come? - A perspective on the acute shortage of pathologists in biomedical research. J Vet Diagn Invest (2007) 1.32
HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res (2005) 1.32
Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth. Cancer Res (2006) 1.30
Hormone-induced protection against mammary tumorigenesis is conserved in multiple rat strains and identifies a core gene expression signature induced by pregnancy. Cancer Res (2006) 1.30